Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of mazdutide (IBI362) in untreated mild-to-moderate hypertension with overweight or obesity
CTR20260680Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Apr 2026
- Modality
- Hormonal Peptides → Native Peptides → Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in hypertension (HTN), obesity, Overweight, sponsored by InnoCare Pharma. Started Apr 2026; status: active.
02
Drugs
mazdutide
03
Conditions
hypertension (HTN)obesityOverweight
Beyond the preview
Go deeper on CTR20260680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260680.